Clinical trial
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or…
NCT00262860 · University of Rochester, Other · Completed
Key facts
| NCT number | NCT00262860 |
|---|---|
| Title | Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
| Official title | Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma |
| Lead sponsor | University of Rochester, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib, gemcitabine hydrochloride |
| Enrollment | 18 |
| Start date | Apr 1, 2005 |
| Primary completion | May 1, 2008 |
| First posted | Dec 7, 2005 |
| Last update posted | May 9, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: